600 mg · vegan · gluten-free · 60 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
KSM-66 is a full-spectrum, standardised root extract of Withania somnifera (ashwagandha) containing 5 % withanolides. A landmark double-blind RCT conducted in Varanasi, India demonstrated that 600 mg/day for 8 weeks significantly improved serum TSH, T3 and T4 in subclinical hypothyroid patients.
Ashwagandha enhances hypothalamic-pituitary-thyroid axis activity, increases T3 and T4 synthesis in the thyroid gland and improves peripheral conversion of T4 to T3. Its antioxidant withanolides also protect thyrocytes from oxidative stress that can precipitate autoimmune damage.
Adults with subclinical hypothyroidism (TSH 4.5–10 µIU/mL, normal free T4), those with stress-related thyroid dysfunction and individuals seeking an Ayurvedic alternative or adjunct to conventional thyroid management.
Avoid in hyperthyroidism, during pregnancy (Denmark and France have issued cautions) and in hormone-sensitive prostate cancer. Use caution in autoimmune conditions beyond Hashimoto's. Side effects: Generally well tolerated; rare mild GI upset, drowsiness or headache. Three case reports of thyrotoxicosis exist at very high doses (>1,950 mg/day) or in susceptible individuals.
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: PMID 28829155 (Sharma 2018 — double-blind RCT in Varanasi, India: 600 mg ashwagandha normalises TSH, T3 and T4 in subclinical hypothyroidism), PMID PMC9035336 (case reports of thyrotoxicosis with high-dose ashwagandha — rare but documented), PMID PMC4308793 (L-tyrosine improves neuroendocrine function in chronic stress — mechanistic parallel for adaptogenic thyroid support)
SacredBod's longer take on Ashwagandha Thyroid TSH — context the structured blocks above don't capture.
Ashwagandha Thyroid TSH features KSM-66, the most clinically studied ashwagandha extract and the only one with a dedicated thyroid RCT. Conducted at Sudbhawana Hospital in Varanasi, India, the 2018 Sharma trial randomised 50 subclinical hypothyroid patients to receive either 600 mg/day of ashwagandha root extract or placebo for 8 weeks. The results were striking: TSH dropped significantly, while T3 and T4 rose significantly — effectively normalising thyroid indices in a population that had not yet progressed to overt hypothyroidism.
| Goal | Dose | Timing |
|---|---|---|
| Subclinical hypothyroidism | 600 mg KSM-66/day | 300 mg with breakfast, 300 mg with dinner |
| General thyroid-adrenal support | 300–600 mg KSM-66/day | With meals |
Use KSM-66 specifically — this is the extract used in the Sharma thyroid RCT. Other extracts (Sensoril, generic root powder) have different withanolide profiles and have not been tested in thyroid-specific trials.
Ashwagandha is remarkably safe at 600 mg/day. The Sharma trial reported only 1 mild adverse event in the treatment group versus 3 in placebo. However, three case reports document thyrotoxicosis in women taking very high doses (1,950 mg/day) or in those with underlying thyroid autonomy. Denmark and France have cautioned against use in pregnancy. Always monitor TSH, T3 and T4 when combining with thyroid medications.
Ashwagandha is the crown jewel of Ayurvedic Rasayana therapy. Charaka Samhita describes it as having the “smell of a horse and the strength of a horse” — Ashwa (horse) + Gandha (smell). It is used for Vata disorders, weakness, emaciation, impotence and nervous exhaustion. The classical indication for thyroid-like symptoms would fall under Galaganda (goitre) and Agnimandya (diminished metabolic fire) — conditions where ashwagandha’s warming, strengthening and stimulating properties are traditionally applied. The modern RCT evidence validates this empirical use for subclinical hypothyroidism.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
